FDA Finds Traces Of Probable Carcinogen In Some Heartburn Drugs

SMS
FDA Finds Traces Of Probable Carcinogen In Some Heartburn Drugs
​The FDA says Zantac-brand heartburn medicines contain small amounts of a known "probable carcinogen."
SHOW TRANSCRIPT

The FDA has found certain over-the-counter heartburn medicines may contain a probable carcinogen.

In a statement released Friday, the FDA said some ranitidine medicines, including prescription drugs and over-the-counter heartburn medicines, contain low levels of a compound called NDMA. NDMA is classified as "a probable human carcinogen," or a substance that could cause cancer.

Specifically, the FDA said Zantac-brand heartburn medicines contained the NDMA impurity.

The FDA has been investigating NDMA since last year and "is evaluating whether the low levels of NDMA in ranitidine pose a risk to patients."

The FDA does not currently recommend that ranitidine users stop taking the drug. But it says people who would rather avoid it can use a different OTC heartburn medicine or ask their health care provider about an alternative prescription drug.

Additional reporting from Newsy affiliate CNN.